Testing a drug-boost to improve olaparib levels and side effects
Treatments studied
Part of Cancer clinical trials.
This Phase 4 study tests whether adding a “booster” medicine can raise olaparib levels in the body so it may be better tolerated and more cost-effective. You may be eligible if you are already taking olaparib and meet health and medication safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign informed consent before screening
- You are able to complete the study measurements or outcomes planned by the team
- You take olaparib tablets 300 mg twice daily (or are starting them by your doctor)
- Your activity/fitness score (ECOG) is within the study range (0–1 for Part A, 0–3 for Part B)
- You are not using other anti-cancer treatments at the same time
- You are not taking strong medicines that speed up or block CYP3A4 (per the study’s Dutch database rules)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares how the body processes a new formulation of olaparib (DWZ2501) versus the standard version. It is for women with advanced, BRCA-mutated high-grade ovarian cancer who are already on or about to start a stable dose of olaparib 300 mg twice daily.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests whether the drug olaparib can help people with advanced pancreatic cancer that has a specific change in the PALB2 gene. You may qualify if your cancer has spread or cannot be removed with surgery and you have already tried at least one other treatment.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.